| Company Name: |
Nantong Hi-Future Biotechnology Co., Ltd
|
| Tel: |
18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:MB710
CAS:2230044-57-0
Purity:98%+ HPLC Package:10mg，100mg，500mg，1g，2g，5g，10g，more
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-1647117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:2-(Diethylamino)-5-hydroxy-6-iodo-7-(1H-pyrrol-1-yl)benzo[d]thiazole-4-carboxylic acid
CAS:2230044-57-0
Purity:99% Package:5mg;10mg;25mg;50mg;100mg Remarks:BD01421169
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:MB710
CAS:2230044-57-0
Package:50mg/RMB 22375;25mg/RMB 17200
|
|
| Product Name: | MB710 | | Synonyms: | MB710;4-Benzothiazolecarboxylic acid, 2-(diethylamino)-5-hydroxy-6-iodo-7-(1H-pyrrol-1-yl)-;2-(Diethylamino)-5-hydroxy-6-iodo-7-(1-pyrrolyl)benzothiazole-4-carboxylic Acid;2-(Diethylamino)-5-hydroxy-6-iodo-7-(1H-pyrrol-1-yl)benzo[d]thiazole-4-carboxylic acid | | CAS: | 2230044-57-0 | | MF: | C16H16IN3O3S | | MW: | 457.29 | | EINECS: | | | Product Categories: | | | Mol File: | 2230044-57-0.mol |  |
| | MB710 Chemical Properties |
| Boiling point | 528.7±60.0 °C(Predicted) | | density | 1.80±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | -0.21±0.40(Predicted) | | color | Light yellow to green yellow |
| | MB710 Usage And Synthesis |
| Uses | MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a Kd of 4.1 μM. MB710 shows anticancer activity in p53-Y220C cell lines[1]. | | Biological Activity | MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a Kd of 4.1?μM. MB710 shows anticancer activity in p53-Y220C cell lines[1].
MB710 (0-200 μM; 72 hours) shows relatively low toxicity against all cell lines tested at concentrations up to 60?μM, while showing initial selective viability reduction at higher concentrations[1].MB710 (72 hours) treats cancer cell lines NUGC3, NUGC4, WI38 and SW1088, with IC50s of 90, 120, >120, >120 μM, respectively[1].MB710 (0-120 μM; 72 hours; HUH-7 cells) shows stronger cytotoxic effects in presence of p53-Y220C[1]. | | References | [1]. Baud MGJ, et al. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur J Med Chem. 2018;152:101-114. |
| | MB710 Preparation Products And Raw materials |
|